Dapagliflozin was similarly efficacious and safe in patients who were and who were not taking sacubitril/valsartan in the DAPA-HF trial, which suggested that the use of both agents together could further lower morbidity and...
the DAPA-HF trial demonstrated a benefit of dapagliflozin to reduce major adverse outcomes in patients with established heart failure with a reduced ejection fraction. The trial sheds light on potential mechanisms
, DAPA-HF Trial Committees and Investigators Dapagliflozin in patients with heart failure and reduced ejection fraction N. Engl. J. Med. (2019), 10.1056/NEJMoa1911303 Published online September 19, 2019 Google Scholar Scirica et al., 2013 B.M. Scirica, D.L. Bhatt, E. Braunwald, P.G. ...
a–f, Effect of dapagliflozin on: death from CV causes (a); death from all causes (b); the total number of hospital admissions for HF (c); time to first hospital admission for HF (d); death from CV causes, MI or stroke (e); and death from CV causes or hospital admission for HF...